S&P 500   2,996.07 (-0.35%)
DOW   26,788.51 (-0.15%)
QQQ   191.85 (-0.80%)
AAPL   239.96 (-0.23%)
FB   182.33 (-3.92%)
MSFT   136.39 (-1.47%)
GOOGL   1,241.75 (-0.20%)
AMZN   1,765.86 (-1.11%)
CGC   21.10 (+3.69%)
NVDA   195.91 (-0.05%)
MU   44.66 (-1.24%)
BABA   169.81 (-2.14%)
GE   9.06 (+3.07%)
TSLA   255.58 (+0.82%)
AMD   31.51 (-1.62%)
T   38.18 (-0.13%)
F   9.07 (+0.44%)
ACB   3.59 (-2.71%)
PRI   125.77 (+0.06%)
NFLX   266.69 (-4.09%)
BAC   31.18 (+0.52%)
GILD   65.88 (+1.03%)
DIS   132.41 (+1.65%)
S&P 500   2,996.07 (-0.35%)
DOW   26,788.51 (-0.15%)
QQQ   191.85 (-0.80%)
AAPL   239.96 (-0.23%)
FB   182.33 (-3.92%)
MSFT   136.39 (-1.47%)
GOOGL   1,241.75 (-0.20%)
AMZN   1,765.86 (-1.11%)
CGC   21.10 (+3.69%)
NVDA   195.91 (-0.05%)
MU   44.66 (-1.24%)
BABA   169.81 (-2.14%)
GE   9.06 (+3.07%)
TSLA   255.58 (+0.82%)
AMD   31.51 (-1.62%)
T   38.18 (-0.13%)
F   9.07 (+0.44%)
ACB   3.59 (-2.71%)
PRI   125.77 (+0.06%)
NFLX   266.69 (-4.09%)
BAC   31.18 (+0.52%)
GILD   65.88 (+1.03%)
DIS   132.41 (+1.65%)
Log in

BioTime Stock Price, News & Analysis (NYSEAMERICAN:BTX)

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume338,078 shs
Average Volume719,479 shs
Market Capitalization$148.76 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNYSEAMERICAN:BTX
Previous SymbolNYSEMKT:BTX
CUSIP09066L10
Phone+1-510-5213390

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees76
Market Cap$148.76 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive BTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BTX and its competitors with MarketBeat's FREE daily newsletter.


BioTime (NYSEAMERICAN:BTX) Frequently Asked Questions

What is BioTime's stock symbol?

BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."

How were BioTime's earnings last quarter?

BioTime, Inc. (NYSEAMERICAN:BTX) posted its quarterly earnings results on Thursday, August, 8th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01. The biotechnology company earned $0.78 million during the quarter, compared to analyst estimates of $1.04 million. View BioTime's Earnings History.

When is BioTime's next earnings date?

BioTime is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for BioTime.

What price target have analysts set for BTX?

6 equities research analysts have issued 1-year target prices for BioTime's stock. Their forecasts range from $3.00 to $5.00. On average, they anticipate BioTime's share price to reach $3.80 in the next twelve months. View Analyst Price Targets for BioTime.

What is the consensus analysts' recommendation for BioTime?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTime in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTime.

What are Wall Street analysts saying about BioTime stock?

Here are some recent quotes from research analysts about BioTime stock:
  • 1. According to Zacks Investment Research, "BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime's research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications. " (8/9/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $4 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based on the opportunities for OpRegen (approximately 57% valuation contribution) on only the U.S. opportunity and Renevia (43% valuation contribution) in the E.U. We note that our current projected values for both these assets are based on minimal market penetration in very large markets." (8/9/2019)
  • 3. Maxim Group analysts commented, "BioTime announced that its affiliate, OncoCyte (OCX – NR, BTX has 36% stake), reported positive results from an R&D validation study of DetermaVu, a non- invasive, liquid biopsy test for the early diagnosis of lung cancer. On this news, BioTime shares on 1/29 were up ~50%, OncoCyte shares were up over 200%, and even Asterias (AST – NR) shares, a cell therapy company soon to be fully acquired by BioTime, were up ~45%." (1/30/2019)

Has BioTime been receiving favorable news coverage?

Media headlines about BTX stock have been trending extremely negative on Tuesday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioTime earned a media sentiment score of -4.3 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for BioTime.

Who are some of BioTime's key competitors?

What other stocks do shareholders of BioTime own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioTime investors own include Geron (GERN), Asterias Biotherapeutics (AST), CA (CA), Micron Technology (MU), Endologix (ELGX), Opko Health (OPK), BlackRock (BLK), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU) and Cisco Systems (CSCO).

Who are BioTime's key executives?

BioTime's management team includes the folowing people:
  • Mr. William Annett, Pres & CEO of OncoCyte Corp. (Age 65)
  • Dr. Stephana E. Patton, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 48)
  • Mr. Brian M. Culley, CEO, Pres & Director (Age 48)
  • Ms. Brandi L. Roberts, CFO & Sec. (Age 45)
  • Ioana C. Hone, Director of Investor Relations

How do I buy shares of BioTime?

Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

How big of a company is BioTime?

BioTime has a market capitalization of $0.00. BioTime employs 76 workers across the globe.View Additional Information About BioTime.

What is BioTime's official website?

The official website for BioTime is http://www.biotimeinc.com/.

How can I contact BioTime?

BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390.


MarketBeat Community Rating for BioTime (NYSEAMERICAN BTX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  192 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  376
MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe BTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Featured Article: Range Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel